Bavarian Nordic

Kvistgard, Denmark Founded: 1994 • Age: 32 yrs Listed
Therapeutic vaccines for cancer and infectious diseases are developed.

About Bavarian Nordic

Bavarian Nordic is a publicly listed company based in Kvistgard (Denmark) founded in 1994. Therapeutic vaccines for cancer and infectious diseases are developed. It operates on a Professional Services model. The company has 1,610 employees. Its website bavarian-nordic.com draws about 32 thousand monthly visits. Bavarian Nordic offers products and services including Vaccines. Its focus areas include Biotechnology and Vaccines. Its legal entity is Bavarian Nordic A/S.

Company details

Bavarian Nordic is engaged in the research, development, and manufacturing of innovative vaccines aimed at protecting public health. The company operates within the biotechnology sector, focusing on life-changing solutions to address global health challenges. Operations span across multiple international locations, ensuring a broad reach and impact through advanced vaccine technologies and dedicated resources for healthcare professionals.

  • Headquarters Kvistgard, Denmark
  • Employees 1,610
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website bavarian-nordic.com
  • Social LinkedIn X Facebook
  • Legal Name Bavarian Nordic A/S
Key Metrics
  • Annual Revenue
    $970.66 M (USD)
    8.06
    as on Dec 31, 2025
  • Net Profit
    $217.1 M (USD)
    39.21
    as on Dec 31, 2025
  • EBITDA
    $258 M (USD)
    4.87
    as on Dec 31, 2025
  • Latest Funding Round
    $183.43M (USD), Post-IPO

    Mar 2021

  • Employee Count
    1,610

Products & Services of Bavarian Nordic

Bavarian Nordic offers a comprehensive portfolio of products and services, including Vaccines.

Vaccines
Healthcare

Innovative life-saving vaccines are developed and manufactured here.

Funding Insights of Bavarian Nordic

  • Total Rounds 1
  • Last Round Post-IPO β€” $183.43M
  • First Round $183.43M

    (Mar 2021)

All 1 funding rounds of Bavarian Nordic with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2021$183.43MPost-IPO––
–

People of Bavarian Nordic

287 people are tracked at Bavarian Nordic (95 in leadership, 10 in board & advisors, 182 in team); the tracked headcount is 1,610.

NameRoleGroup
Laurence De Moerlooze
EVP & Chief Medical OfficerLeadership
Pascal Schwarz
Director, Manufacturing, Science And Technology (ms&t)Leadership
Tommi Kainu
Executive Vice President, Chief Business OfficerLeadership
Adele Marthaler
Head Of Contract Manufacturing SolutionsLeadership
Demetria B.
Human Resources DirectorLeadership
Heidi Ringer Dethlefsen
Finance DirectorLeadership
Carolin S.
Head Assay DevelopmentLeadership
Britt Juul Christensen
Senior Vice President QualityLeadership
Ken Carlo Iledan
Head Of Clinical OperationsLeadership
Baptiste Leclerc
Manager CMOLeadership
Helle Thanning
Senior HR Business PartnerLeadership
Henrik Juuel
Executive Vice President, Chief Financial OfficerLeadership
Paul Chaplin
President & CEOLeadership
Jean-Christophe May
EVP & Chief Commercial OfficerLeadership
Russell Thirsk
EVP & COOLeadership
Joe Kukolla
Associate Director Of MarketingLeadership
James G. Burns
Director, Medical Affairs, CanadaLeadership
Alexandra S.
Vice President Commercial, Germany And SwitzerlandLeadership
Claes Axäng
Director R D And CSPV QALeadership
Bernard Hoet
Vice President Of Medical Strategy At Bavarian NordicLeadership

267 more people are available in the full profile.

Premium access

Complete people profiles for Bavarian Nordic

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Bavarian Nordic

Bavarian Nordic is a publicly listed company on the OMXCOP with ticker symbol BAVA in Denmark, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date07 Jan 2000
  • Listed onSTO: BAVA
  • Listed entityBavarian Nordic A/S
  • Exchange sectorHealth technology
  • ISINDK0015998017
  • Share price236.80 DKK · 2026-10-14
  • Market capitalisation18,744,536,277.00 DKK
  • Price to earnings11.8
  • EPS (diluted, trailing year)20.00 DKK
  • Volume (last session)129,652

Financials of Bavarian Nordic

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
20256.17B DKK1.38B DKK1.64B DKK
20245.71B DKK988.0M DKK1.56B DKK
20237.06B DKK1.48B DKK2.05B DKK
20223.15B DKK-347.4M DKK328.5M DKK
20211.89B DKK-464.8M DKK67.7M DKK
Premium access

Detailed financial statements for Bavarian Nordic

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Bavarian Nordic

3 dated milestones of Bavarian Nordic across 27 years, from founding to its latest funding, stage changes and deals.

  1. Founded Bavarian Nordic is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $183.4M.

Web traffic of Bavarian Nordic

The website of Bavarian Nordic (bavarian-nordic.com) receives about 31.7K visits a month and ranks #762,962 among all websites worldwide, #892 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    31.7K

    ▼ 20.8% vs previous month

  • Unique visitors
    14.1K

    per month

  • Global rank
    #762,962

    among all websites

  • Category rank
    #892

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Bavarian Nordic. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
lundbeck.com
100%
137.6K#280,857View details
vical.com
100%
View details
crucell.com
93%
View details
gskvaccines.com
gskvaccines.com
88%
–
arthurdovermd.com
arthurdovermd.com
86%
–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 16 similar websites and full traffic analytics for Bavarian Nordic

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 16 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Bavarian Nordic

Premium access

Complete news archive for Bavarian Nordic

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bavarian Nordic

Bavarian Nordic was founded in 1994 and raised its 1st funding round 27 years after it was founded.

Bavarian Nordic is headquartered in Kvistgard, Denmark.

Bavarian Nordic has 1,610 employees.

Annual revenue of Bavarian Nordic is $970.66M as on Dec 31, 2025.

Bavarian Nordic is engaged in the research, development, and manufacturing of innovative vaccines aimed at protecting public health. The company operates within the biotechnology sector, focusing on life-changing solutions to address global health challenges. Operations span across multiple international locations, ensuring a broad reach and impact through advanced vaccine technologies and dedicated resources for healthcare professionals.

Bavarian Nordic offers Vaccines.

Yes, Bavarian Nordic is publicly traded on OMXCOP under the ticker symbol BAVA.

Bavarian Nordic operates through Bavarian Nordic A/S.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available